Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Clinical and prognostic characteristics of bilateral Wilms tumor: a multi-center institutional retrospective cohort study experience from China.

World journal of pediatrics : WJP·2025

Same author

Biallelic inactivation of <i>SDHA</i> results in comorbidity of pediatric recurrent neuroblastoma and gastric stromal tumor.

Genes & diseases·2024

Same author

International Society of Paediatric Surgical Oncology (IPSO): A Short History, Developments, and Current Status.

Journal of pediatric surgery·2024

Same author

Editorial: Recent advances in organ-sparing techniques in pediatric solid tumor surgery.

Frontiers in pediatrics·2023

Same author

International Society of Paediatric Surgical Oncology (IPSO) Surgical Practice Guidelines.

Ecancermedicalscience·2022

Same author

Treatment of Ewing sarcoma in children: Results from a single centre.

Annals of the Academy of Medicine, Singapore·2021

Search research articles

Related Experiment Video

Updated: Jul 13, 2026

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies

Published on: July 28, 2020

Nonrhabdomyosarcoma soft tissue sarcoma (NRSTS).

Chan Hon Chui¹

¹Department of Pediatric Surgery, KK Women's and Children's Hospital, 100 Bukit Timah Road, Singapore 229 899, Singapore. chchui@surgeryforchildren.com

Surgical Oncology

|August 21, 2007

Summary

Nonrhabdmyosarcoma soft tissue sarcoma (NRSTS) presents diverse subtypes. Advances in diagnosis and multimodality treatments, including surgery and chemotherapy, improve outcomes, but novel targeted therapies are needed for metastatic disease.

More Related Videos

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Published on: September 13, 2019

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

Related Experiment Videos

Last Updated: Jul 13, 2026

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies

Published on: July 28, 2020

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Published on: September 13, 2019

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

Area of Science:

Oncology
Pathology
Surgical Oncology

Background:

Nonrhabdmyosarcoma soft tissue sarcoma (NRSTS) is a rare, heterogeneous group of tumors.
Existing data primarily comes from adult or pediatric case studies.
Recent multi-center reports evaluate prognostic factors and treatment protocols.

Purpose of the Study:

To review established prognostic factors for NRSTS.
To discuss current treatment modalities and their evolution.
To highlight the need for novel therapeutic strategies.

Main Methods:

Review of established prognostic factors: tumor grade, invasiveness, size, and IRS group.
Analysis of diagnostic advancements, including chromosomal translocations.
Evaluation of surgical management and multimodality treatment protocols.

Main Results:

Prognostic factors like grade, invasiveness, and size are established.
Chromosomal translocations aid diagnosis and may offer therapeutic targets.
Surgery remains crucial due to limited chemosensitivity; multimodality approaches evolve.

Conclusions:

Localized unresectable NRSTS shows good results with surgery +/- radiotherapy.
Metastatic NRSTS has a poor prognosis despite chemotherapy and surgery.
Future research should focus on molecular techniques for targeted therapies and histology-specific trials.